ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. announced today that Mr. Nordhoff has been elected Executive Chairman of the Board for Banyan Biomarkers, Inc.
Mr. Nordhoff joins Banyan Biomarkers, Inc. from Gen-Probe Incorporated where he served as President, Chairman, and CEO from 1994 until his retirement in 2009. He served as non-executive Chairman until the end of 2011. Prior to Gen-Probe, Mr. Nordhoff served as CEO of TargeTech, Inc. and American Biogenetic Sciences, after devoting 16 years with Pfizer, Inc. in senior positions in Europe, Asia, and New York. Mr. Nordhoff received a BA in International Relations and Political Economics from Johns Hopkins University and an MBA from Columbia University. During his 17 year tenure at Gen-Probe and its successful spinoff in 1994, Mr. Nordhoff led the company to over $500mm in revenues. "Hank Nordhoff is a diagnostics industry titan and we are fortunate to have him be a part of our team as we work to bring traumatic brain injury diagnostic tests to the patient,” added Jackson Streeter, MD, Chief Executive Officer of Banyan Biomarkers. “I am delighted to join the Banyan team and help the Company grow and commercialize the TBI diagnostics and fill this vital, unmet need,” stated Mr. Nordhoff.
About Banyan Biomarkers
Banyan Biomarkers is a spinout company from the University of Florida and is the leader in developing brain injury in vitro diagnostics. The Company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. To learn more about Banyan Biomarkers, Inc. visit http://www.banyanbio.com.